Severe acute liver injury associated with lumiracoxib
Journal of Gastroenterology and Hepatology,  Clinical Article

Pillans PI et al. – Lumiracoxib can be associated with severe liver injury. The presence of a variety of positive auto–antibodies suggests an altered immune response may be contributory.

  • To describe in detail 3 cases of severe liver injury in patients taking lumiracoxib who were admitted to the hospital, together with information on a further 6 cases reported to the Australian Therapeutics Goods Administration (TGA), none of whom had pre-existing liver disease or obvious risk factors for liver disease.

  • Liver histology showed severe hepatic necrosis.
  • One patient required liver transplantation and another died.
  • Autoantibodies were detected in all 3 patients.
  • As with the other 6 cases reported to the TGA, all were females who had been taking lumiracoxib 200-400 mg daily, typically for a few months, for osteoarthritis.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Physician Assistant

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Physician Assistant Articles

Indexed Journals in Physician Assistant: Advance for Physicians Assistants, American Family Physicianmore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More